Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Janux Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Janux Therapeutics Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/03/2025 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth53% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
02/28/2025 | Buy Now | — | Scotiabank | George Farmer43% | $62 → $41 | Maintains | Sector Perform | Get Alert |
12/11/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer57% | $200 → $200 | Reiterates | Overweight → Overweight | Get Alert |
12/04/2024 | Buy Now | — | Scotiabank | George Farmer43% | $42 → $62 | Maintains | Sector Perform | Get Alert |
12/03/2024 | Buy Now | — | Stifel | Bradley Canino41% | $70 → $115 | Maintains | Buy | Get Alert |
12/03/2024 | Buy Now | — | Leerink Partners | Jeffrey La Rosa19% | $79 → $91 | Maintains | Outperform | Get Alert |
12/03/2024 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth53% | $63 → $70 | Maintains | Buy | Get Alert |
11/22/2024 | Buy Now | — | Leerink Partners | Jeffrey La Rosa19% | → $79 | Initiates | → Outperform | Get Alert |
11/07/2024 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth53% | $63 → $63 | Reiterates | Buy → Buy | Get Alert |
11/07/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer57% | $100 → $100 | Reiterates | Overweight → Overweight | Get Alert |
10/24/2024 | Buy Now | — | UBS | David Dai28% | → $69 | Initiates | → Buy | Get Alert |
09/16/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer57% | $100 → $100 | Reiterates | Overweight → Overweight | Get Alert |
09/06/2024 | Buy Now | — | Stifel | Bradley Canino41% | → $70 | Initiates | → Buy | Get Alert |
08/19/2024 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth53% | $63 → $63 | Reiterates | Buy → Buy | Get Alert |
08/09/2024 | Buy Now | — | Scotiabank | George Farmer43% | $47 → $42 | Maintains | Sector Perform | Get Alert |
08/08/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer57% | $100 → $100 | Reiterates | Overweight → Overweight | Get Alert |
08/08/2024 | Buy Now | — | Wedbush | Robert Driscoll44% | $74 → $74 | Reiterates | Outperform → Outperform | Get Alert |
05/30/2024 | Buy Now | — | Scotiabank | George Farmer43% | → $47 | Initiates | → Sector Perform | Get Alert |
05/13/2024 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth53% | $50 → $63 | Maintains | Buy | Get Alert |
05/09/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer57% | $100 → $100 | Reiterates | Overweight → Overweight | Get Alert |
05/08/2024 | Buy Now | — | Wedbush | Robert Driscoll44% | $53 → $74 | Maintains | Outperform | Get Alert |
04/16/2024 | Buy Now | — | JonesTrading | Soumit Roy37% | → $70 | Initiates | → Buy | Get Alert |
03/21/2024 | Buy Now | — | BTIG | Kaveri Pohlman27% | → $62 | Initiates | → Buy | Get Alert |
03/20/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer57% | → $100 | Initiates | → Overweight | Get Alert |
03/13/2024 | Buy Now | — | B of A Securities | Geoff Meacham62% | $24 → $48 | Maintains | Buy | Get Alert |
03/11/2024 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth53% | $35 → $50 | Maintains | Buy | Get Alert |
02/27/2024 | Buy Now | — | Wedbush | David Driscoll52% | $24 → $53 | Maintains | Outperform | Get Alert |
11/13/2023 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth53% | → $35 | Reiterates | Buy → Buy | Get Alert |
11/08/2023 | Buy Now | — | Wedbush | Robert Driscoll44% | → $24 | Reiterates | Outperform → Outperform | Get Alert |
08/10/2023 | Buy Now | — | Wedbush | Robert Driscoll44% | → $24 | Reiterates | Outperform → Outperform | Get Alert |
08/09/2023 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth53% | → $35 | Reiterates | Buy → Buy | Get Alert |
07/18/2023 | Buy Now | — | Wedbush | Robert Driscoll44% | → $24 | Reiterates | Outperform → Outperform | Get Alert |
07/18/2023 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth53% | → $35 | Reiterates | Buy → Buy | Get Alert |
05/10/2023 | Buy Now | — | Wedbush | Robert Driscoll44% | → $24 | Reiterates | → Outperform | Get Alert |
05/10/2023 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth53% | → $35 | Reiterates | → Buy | Get Alert |
04/06/2023 | Buy Now | — | Wedbush | Robert Driscoll44% | → $24 | Initiates | → Outperform | Get Alert |
03/13/2023 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth53% | → $35 | Reiterates | → Buy | Get Alert |
11/14/2022 | Buy Now | — | William Blair | Matt Phipps25% | — | Initiates | → Outperform | Get Alert |
The latest price target for Janux Therapeutics (NASDAQ:JANX) was reported by HC Wainwright & Co. on March 3, 2025. The analyst firm set a price target for $70.00 expecting JANX to rise to within 12 months (a possible 201.98% upside). 17 analyst firms have reported ratings in the last year.
The latest analyst rating for Janux Therapeutics (NASDAQ:JANX) was provided by HC Wainwright & Co., and Janux Therapeutics reiterated their buy rating.
There is no last upgrade for Janux Therapeutics
There is no last downgrade for Janux Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Janux Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Janux Therapeutics was filed on March 3, 2025 so you should expect the next rating to be made available sometime around March 3, 2026.
While ratings are subjective and will change, the latest Janux Therapeutics (JANX) rating was a reiterated with a price target of $70.00 to $70.00. The current price Janux Therapeutics (JANX) is trading at is $23.18, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.